Pomerantz LLP is investigating claims on behalf of investors of T-Mobile US, Inc.(“T-Mobile” or the “Company”) (NASDAQ: TMUS).Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether T-Mobile and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for […]

NEW YORK CITY, NY / ACCESS Newswire / June 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NeuroPace, Inc. ("NeuroPace" or "the Company") (NASDAQ:NPCE). Investors who purchased NeuroPace securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/NPCE. Investigation

NEW YORK, NY / ACCESS Newswire / June 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NANO Nuclear Energy Inc. ("NNE" or "the Company") (NASDAQ:NNE). Investors who purchased NNE securities prior to May 8, 2024, and continue to hold to the present, are encouraged to obtain

NEW YORK, NY / ACCESS Newswire / June 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AlloVir Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR). Investors who purchased AlloVir securities prior to March 22, 2022, and continue to hold to the present, are encouraged to obtain additional information

Pomerantz LLP is investigating claims on behalf of investors of Senti Biosciences, Inc.(“Senti” or the “Company”) (NASDAQ: SNTI).Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether Senti and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for

Pomerantz LLP is investigating claims on behalf of investors of Landstar System, Inc. (“Landstar” or the “Company”) (NASDAQ: LSTR).Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether Landstar and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here

Pomerantz LLP is investigating claims on behalf of investors of ICU Medical, Inc. (“ICU” or the “Company”) (NASDAQ: ICUI).Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether ICUand certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for

Pomerantz LLP is investigating claims on behalf of investors of Backblaze, Inc.(“Backblaze” or the “Company”) (NASDAQ: BLZE).Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether Backblazeand certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about

Pomerantz LLP is investigating claims on behalf of investors of Semler Scientific Inc.(“Semler” or the “Company”) (NASDAQ: SMLR).Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether Semler and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for

Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. (“NeuroPace” or the “Company”) (NASDAQ: NPCE).Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether NeuroPace and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for